| Toggle Summary
|
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
LAWRENCEVILLE, N.J. , Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m.
|
View HTML
|
| Toggle Summary
|
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
LAWRENCEVILLE, N.J. , July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i)
|
View HTML
|
| Toggle Summary
|
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J. , July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Company’s Board of Directors
|
View HTML
|
| Toggle Summary
|
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit Full Enrollment Expected by Third Quarter of 2022 LAWRENCEVILLE, N.J. , June 21, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-based immunotherapy and
|
View HTML
|
| Toggle Summary
|
Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , May 16, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-development company focused on
|
View HTML
|
| Toggle Summary
|
Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates
PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies Phase II study of GEN-1 in ovarian cancer 85% enrolled with full enrollment expected in the third quarter of 2022 FDA Allows GEN-1 + Avastin Phase II study LAWRENCEVILLE, N.J. , May 10, 2022 (GLOBE NEWSWIRE) -- Celsion
|
View HTML
|
| Toggle Summary
|
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022
LAWRENCEVILLE, N.J. , May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m.
|
View HTML
|
| Toggle Summary
|
Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress
Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus The Goal to Provide Broader Range Protection within a Highly Flexible Platform Appears to Show Promise LAWRENCEVILLE, N.J. , April 21, 2022 (GLOBE NEWSWIRE) -- Celsion
|
View HTML
|
| Toggle Summary
|
Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting
Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR A nnual M eeti ng LAWRENCEVILLE, N.J. , April 14, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) a clinical-stage company focused on DNA-based immunotherapy and
|
View HTML
|
| Toggle Summary
|
Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress
LAWRENCEVILLE, N.J. , April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced it would highlight its PLACCINE platform technology in an oral presentation at the World Vaccine
|
View HTML
|
